Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA. Rodes B, et al. Among authors: ribas ma. J Med Virol. 2005 Sep;77(1):23-8. doi: 10.1002/jmv.20395. J Med Virol. 2005. PMID: 16032728
A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.
Mallolas J, Blanco JL, Pich J, Arnaiz JA, Peña JM, Dalmau D, de Lazzari E, Ochoa A, Vidal F, Ribas MA, Segura F, Pedrol E, Flores J, Cruceta A, Varea S, Miró JM, Martínez E, Gatell JM. Mallolas J, et al. Among authors: ribas ma. Rev Clin Esp. 2007 Oct;207(9):427-32. doi: 10.1157/13109831. Rev Clin Esp. 2007. PMID: 17915162 Clinical Trial.
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS).
Yebra G, de Mulder M, Martín L, Pérez-Cachafeiro S, Rodríguez C, Labarga P, García F, Tural C, Jaén A, Navarro G, Holguín A; Cohort of Spanish AIDS Research Network (CoRIS). Yebra G, et al. Antiviral Res. 2011 Jan;89(1):19-25. doi: 10.1016/j.antiviral.2010.10.008. Epub 2010 Nov 9. Antiviral Res. 2011. PMID: 21070813
Definition of advanced age in HIV infection: looking for an age cut-off.
Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, Pulido F, Asensi V, del Amo J, Moreno S; CoRIS. Blanco JR, et al. AIDS Res Hum Retroviruses. 2012 Sep;28(9):1000-6. doi: 10.1089/AID.2011.0377. AIDS Res Hum Retroviruses. 2012. PMID: 22607516 Free PMC article.
Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.
Monge S, Guillot V, Alvarez M, Peña A, Viciana P, García-Bujalance S, Pérez Elias MJ, Iribarren JA, Gutiérrez F, Itziar Casado M, Garcia F; CoRIS. Monge S, et al. Clin Microbiol Infect. 2012 Nov;18(11):E485-90. doi: 10.1111/1469-0691.12011. Epub 2012 Sep 27. Clin Microbiol Infect. 2012. PMID: 23016666 Free article.
78 results